| dc.description.abstract | Breast cancer affects a variety of individuals and currently encompasses a vast number of treatment plans. Two commonly used agents, Cyclophosphamide (C) and Adriamycin (A), will be used at clinical dosage on a progressive breast cancer cell line model. By studying four cancer cell lines, it enables the examination of breast cancer pathways from precancerous to highly aggressive tumor growth. Preliminary results have shown that the hypoxia inducible factor (HIF) pathway is one of the key pathways altered. Using Real Time PCR, we will study the gene expression changes in HIFa, as well as many additional stress related internal ribosomal entry site (IRES) genes, which aid in tumor growth. In turn, this will emphasize which genes are integral components of critical breast cancer pathways. Target genes, namely HIFa, will be blocked using RNA-i technology, providing possibilities of new cancer treatment and creation of new alternate pathways due to blockage of such genes. Targeting these pathways can lead to inhibiting growth of breast cancer cells and preventing its reoccurrence. | en |
